Meeting Report
The Pharmacogenomics Journal (2006) 6, 78–81. doi:10.1038/sj.tpj.6500345; published online 10 January 2006
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop
- 1Worldwide Regulatory Affairs, Pharma & Translational Medicine, Wyeth Research, Collegeville, PA, USA
- 2Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
Correspondence: Dr RA Salerno, Worldwide Regulatory Affairs, Pharma & Translational Medicine, Wyeth Research, 500 Arcola Road, Collegeville, PA 19454, USA. E-mail: salernr@wyeth.com; LJ Lesko, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. E-mail: leskol@cder.fda.gov